Table 1.
Demographic information of the study participants.
| Group 1 | Group 2 | Total | |
|---|---|---|---|
| Number of participants, n | 10 | 19 | 29 |
| Primary vaccines (Dose 1 and Dose 2) | mRNA | ChAdOx1-S (Covishield) | – |
| Booster vaccines (Dose 3 and Dose 4) | mRNA | mRNA | – |
| Covishield received as primary vaccines, n (%) | – | 19 (100.0) | 19 (65.5) |
| mRNA-1273 (Moderna) received as primary vaccines, n (%) | 9 (90.0) | – | 9 (31.0) |
| BNT162b2 (Pfizer-BioNTech) as primary vaccines, n (%) | 1 (10.0) | – | 1 (3.4) |
| mRNA-1273 (Moderna) received as booster vaccines, n (%) | 6 (60.0) | – | 6 (20.7) |
| BNT162b2 (Pfizer-BioNTech) as booster vaccines, n (%) | 4 (40.0) | – | 4 (13.8) |
| SARS-CoV-2 infection before primary doses, n (%) | 3 (30.0) | 3 (15.7) | 6 (20.7) |
| SARS-CoV-2 infection before booster doses, n (%) | 1 (10.0) | 1 (5.3) | 2 (6.9) |
| Age in years, median (range) | 37.5 (30-53) | 44 (29-60) | 43 (29-60) |
| Sex, n (%) | |||
| Female | 4 (40) | 6 (31.6) | 10 (34.5) |
| Male | 6 (60) | 13 (68.4) | 19 (65.5) |
| Time intervals between vaccination in days, median (range) | |||
| Dose 1 to Dose 2 | 28 (28-29) | 63 (54-76) | – |
| Dose 2 to Dose 3 | 235 (225-338) | 302 (276-312) | – |
| Dose 3 to Dose 4 | 329 (246-371) | 372 (362-388) | – |